News & Publications

By Topic

09.01.23 - publication

A Phase 1b, Open-Label, 2-part, Safety, Tolerability, and Efficacy Study of a Soluble Beta-Glucan (Odetiglucan)

Poster

05.23.23 - news

HiberCell Announces FPD in Ph1b Combination in metastatic PDAC

04.19.23 - publication

Activation of GCN2 by HC-7366 results in significant antitumor efficacy as monotherapy

Poster

04.18.23 - publication

Inhibition of PERK by HC-5404 sensitizes clear cell renal cell carcinoma tumor models

Poster

04.17.23 - publication

Combination therapy using PERK and PD1/PD-L1 inhibitors reduces tumor burden

Poster

03.27.23 - news

HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023

02.22.23 - news

HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML)

01.24.23 - publication

Activation of GCN2 by HC-7366 results in significant anti-tumor efficacy

Poster

11.30.22 - publication

Novel GCN2 Modulator HC-7366 Inhibits Myeloid-derived Suppressor Cells and Reduces Pulmonary Metastases

Poster

11.30.22 - publication

HC-5404 Demonstrates Immune-activation and Anti-tumor Efficacy

Poster

11.02.22 - news

HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

10.28.22 - publication

Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors

Publication

10.26.22 - publication

Cancer immunotherapy via myeloid signaling pathway co-activation

Poster

05.26.22 - publication

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies

Publication

05.24.22 - news

HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting

05.13.22 - news

HiberCell and the University of Pennsylvania Present Preclinical Anti-Metastatic Monotherapy Activity Data in Mice for Odetiglucan in Pancreatic Cancer at AACR Annual Meeting 2022

04.28.22 - news

1st Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® in Adult Patients w/Metastatic, Hormone-Refractory Breast Cancer

03.09.22 - publication

Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer

Publication

03.03.22 - news

HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment

02.24.22 - news

HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors

12.14.21 - news

HiberCell to Collaborate with Merck on Phase 2 Clinical Trial of Odetiglucan in Patients with Metastatic Breast Cancer

12.09.21 - news

HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment at ESMO Immuno-Oncology Virtual Congress 2021

12.07.21 - news

HiberCell To Present New Data on Odetiglucan Plus Pembrolizumab in Ongoing Phase 2 Metastatic Breast Cancer Trial at San Antonio Breast Cancer Symposium

09.30.21 - news

HiberCell Appoints Jonathan Lanfear as COO

09.24.21 - publication

Targeting the Integrated Stress Response in Cancer Therapy

Publication

09.08.21 - news

HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FU

08.16.21 - news

HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.

07.30.21 - publication

PERK inhibition blocks metastasis initiation by limiting UPR-dependent survival of dormant disseminated cancer cells

Publication

06.29.21 - news

HiberCell Appoints Mark J. Mulvihill, Ph.D., Chief Scientific Officer

06.10.21 - news

HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator

05.19.21 - news

HiberCell Closes $67.4 Million Series B Financing and Secures $30 Million Debt Facility from Hercules Capital

04.28.21 - publication

Quantum processor-inspired machine learning in the biomedical sciences

Publication

02.21.21 - publication

Endoplasmic reticulum stress signals in the tumour and its microenvironment

Publication

01.21.21 - news

HiberCell Expands Scientific Advisory Board with Appointment of Lisa M. Coussens, Ph.D., and Ronald Wek, Ph.D.

01.13.21 - news

HiberCell and Biodesix Initiate Broad Collaboration forCompanion Diagnostic Discovery, Development and Commercialization

12.02.20 - news

HiberCell Bolsters Leadership Team with Appointment of Joseph Talamo as Chief Financial Officer and Promotion of Ari Nowacek, M.D., Ph.D., to Chief Business Officer

07.07.20 - news

HiberCell Announces Acquisition of Biothera Pharmaceuticals’ Imprime PGG Program

04.01.20 - publication

A novel, phase 2 study in second line +, metastatic triple negative breast cancer patients shows promising clinical benefit

Abstract

03.10.20 - publication

Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan

Publication

12.04.19 - news

Nature Sponsored Feature – Pioneering the Discovery and Development of Novel Therapeutics to Prevent Metastasis

12.01.19 - publication

Response and clinical benefit assessment of the combination of the dectin-1 agonist Imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

Poster

11.01.19 - publication

Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection

Publication

11.01.19 - publication

Association of immunopharmacodynamic responses of Imprime PGG plus pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects

Poster

11.01.19 - publication

Clinical benefit evident with early immunopharmacodynamic responses in prior checkpoint failed metastatic melanoma patients treated with Imprime PGG and pembrolizumab

Poster

08.06.19 - news

HiberCell Strengthens Leadership Team with Appointment of Colin Goddard to Board of Directors

05.01.19 - publication

Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers

Publication

02.07.19 - news

STAT – New York biotech debuts, targeting dormant metastatic cancer cells

02.07.19 - news

FierceBiotech – Biotech HiberCell launches with $60M+ to combat cancer relapse and metastasis

02.07.19 - news

Endpoints – Arch joins Celgene, China investors bankrolling a pioneering New York biotech startup focused on a new approach to metastasis

02.07.19 - news

HiberCell Launches to Prevent Cancer Relapse and Metastasis with Novel Therapeutics

10.16.18 - news

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

09.28.18 - news

How dormant cancer persists and reawakens

04.01.18 - publication

Imprime (β-1,3/1,6 glucan) synergizes with a CD40 agonist to stimulate T cell-dependent antitumor activity in a poorly immunogenic model of pancreatic carcinoma

Poster

04.01.18 - publication

Imprime PGG synergizes with anti-angiogenic antibodies to repolarize the immune microenvironment, suppressing xenograft tumor growth in vivo

Poster

04.01.18 - publication

Imprime PGG, a soluble yeast β-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing

Poster

02.01.18 - publication

A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer

Publication

12.13.16 - news

Mechanism of early dissemination and metastasis in Her2+ mammary cancer

11.01.16 - publication

Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation

Publication

03.17.15 - publication

Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates

Publication

01.30.15 - news

NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes

08.01.13 - publication

Binding of soluble yeast β-glucan to human neutrophils and monocytes is complement-dependent

Publication

09.01.23 - publication

A Phase 1b, Open-Label, 2-part, Safety, Tolerability, and Efficacy Study of a Soluble Beta-Glucan (Odetiglucan)

Poster

05.23.23 - news

HiberCell Announces FPD in Ph1b Combination in metastatic PDAC

04.19.23 - publication

Activation of GCN2 by HC-7366 results in significant antitumor efficacy as monotherapy

Poster

04.18.23 - publication

Inhibition of PERK by HC-5404 sensitizes clear cell renal cell carcinoma tumor models

Poster

04.17.23 - publication

Combination therapy using PERK and PD1/PD-L1 inhibitors reduces tumor burden

Poster

03.27.23 - news

HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023

02.22.23 - news

HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML)

01.24.23 - publication

Activation of GCN2 by HC-7366 results in significant anti-tumor efficacy

Poster

11.30.22 - publication

Novel GCN2 Modulator HC-7366 Inhibits Myeloid-derived Suppressor Cells and Reduces Pulmonary Metastases

Poster

11.30.22 - publication

HC-5404 Demonstrates Immune-activation and Anti-tumor Efficacy

Poster

11.02.22 - news

HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

10.28.22 - publication

Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors

Publication

10.26.22 - publication

Cancer immunotherapy via myeloid signaling pathway co-activation

Poster

05.26.22 - publication

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies

Publication

05.24.22 - news

HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting

05.13.22 - news

HiberCell and the University of Pennsylvania Present Preclinical Anti-Metastatic Monotherapy Activity Data in Mice for Odetiglucan in Pancreatic Cancer at AACR Annual Meeting 2022

04.28.22 - news

1st Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® in Adult Patients w/Metastatic, Hormone-Refractory Breast Cancer

03.09.22 - publication

Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer

Publication

03.03.22 - news

HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment

02.24.22 - news

HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors

12.14.21 - news

HiberCell to Collaborate with Merck on Phase 2 Clinical Trial of Odetiglucan in Patients with Metastatic Breast Cancer

12.09.21 - news

HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment at ESMO Immuno-Oncology Virtual Congress 2021

12.07.21 - news

HiberCell To Present New Data on Odetiglucan Plus Pembrolizumab in Ongoing Phase 2 Metastatic Breast Cancer Trial at San Antonio Breast Cancer Symposium

09.30.21 - news

HiberCell Appoints Jonathan Lanfear as COO

09.24.21 - publication

Targeting the Integrated Stress Response in Cancer Therapy

Publication

09.08.21 - news

HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FU

08.16.21 - news

HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.

07.30.21 - publication

PERK inhibition blocks metastasis initiation by limiting UPR-dependent survival of dormant disseminated cancer cells

Publication

06.29.21 - news

HiberCell Appoints Mark J. Mulvihill, Ph.D., Chief Scientific Officer

06.10.21 - news

HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator

05.19.21 - news

HiberCell Closes $67.4 Million Series B Financing and Secures $30 Million Debt Facility from Hercules Capital

04.28.21 - publication

Quantum processor-inspired machine learning in the biomedical sciences

Publication

02.21.21 - publication

Endoplasmic reticulum stress signals in the tumour and its microenvironment

Publication

01.21.21 - news

HiberCell Expands Scientific Advisory Board with Appointment of Lisa M. Coussens, Ph.D., and Ronald Wek, Ph.D.

01.13.21 - news

HiberCell and Biodesix Initiate Broad Collaboration forCompanion Diagnostic Discovery, Development and Commercialization

12.02.20 - news

HiberCell Bolsters Leadership Team with Appointment of Joseph Talamo as Chief Financial Officer and Promotion of Ari Nowacek, M.D., Ph.D., to Chief Business Officer

07.07.20 - news

HiberCell Announces Acquisition of Biothera Pharmaceuticals’ Imprime PGG Program

04.01.20 - publication

A novel, phase 2 study in second line +, metastatic triple negative breast cancer patients shows promising clinical benefit

Abstract

03.10.20 - publication

Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan

Publication

12.04.19 - news

Nature Sponsored Feature – Pioneering the Discovery and Development of Novel Therapeutics to Prevent Metastasis

12.01.19 - publication

Response and clinical benefit assessment of the combination of the dectin-1 agonist Imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

Poster

11.01.19 - publication

Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection

Publication

11.01.19 - publication

Association of immunopharmacodynamic responses of Imprime PGG plus pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects

Poster

11.01.19 - publication

Clinical benefit evident with early immunopharmacodynamic responses in prior checkpoint failed metastatic melanoma patients treated with Imprime PGG and pembrolizumab

Poster

08.06.19 - news

HiberCell Strengthens Leadership Team with Appointment of Colin Goddard to Board of Directors

05.01.19 - publication

Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers

Publication

02.07.19 - news

STAT – New York biotech debuts, targeting dormant metastatic cancer cells

02.07.19 - news

FierceBiotech – Biotech HiberCell launches with $60M+ to combat cancer relapse and metastasis

02.07.19 - news

Endpoints – Arch joins Celgene, China investors bankrolling a pioneering New York biotech startup focused on a new approach to metastasis

02.07.19 - news

HiberCell Launches to Prevent Cancer Relapse and Metastasis with Novel Therapeutics

10.16.18 - news

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

09.28.18 - news

How dormant cancer persists and reawakens

04.01.18 - publication

Imprime (β-1,3/1,6 glucan) synergizes with a CD40 agonist to stimulate T cell-dependent antitumor activity in a poorly immunogenic model of pancreatic carcinoma

Poster

04.01.18 - publication

Imprime PGG synergizes with anti-angiogenic antibodies to repolarize the immune microenvironment, suppressing xenograft tumor growth in vivo

Poster

04.01.18 - publication

Imprime PGG, a soluble yeast β-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing

Poster

02.01.18 - publication

A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer

Publication

12.13.16 - news

Mechanism of early dissemination and metastasis in Her2+ mammary cancer

11.01.16 - publication

Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation

Publication

03.17.15 - publication

Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates

Publication

01.30.15 - news

NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes

08.01.13 - publication

Binding of soluble yeast β-glucan to human neutrophils and monocytes is complement-dependent

Publication